血液检测风险预测模型CPH-Lung用于肺癌风险分层
基于丹麦两个前瞻性人群队列,开发并验证了纳入血液检测信息的6年肺癌风险模型CPH-Lung。
核心结论
- 在丹麦人群中,纳入血液检测信息后,CPH-Lung模型对6年肺癌风险的预测灵敏度优于PLCOm2012,尤其在女性和年轻个体中。
研究设计与样本
- 基于两个前瞻性一般人群队列建模6年肺癌风险:CGPS用于训练,CCHS用于验证。
- 训练集为CGPS中689例肺癌病例和1,924例对照的吸烟者。
- 验证集为CCHS中年龄≥50岁的3,195名吸烟者,并与PLCOm2012模型比较。
主要发现
- CGPS和CCHS分别有689例和68例6年肺癌事件。
关键数值与推荐
- CPH-Lung模型在CCHS验证中AUC为0.783(95%CI 0.731-0.835)。
- PLCOm2012模型在CCHS验证中AUC为0.720(95%CI 0.669-0.770)。
临床怎么用
- CPH-Lung模型可在影像学筛查前利用血液检测信息改善肺癌风险分层,尤其对女性和年轻吸烟者可能提高高风险个体识别灵敏度。
局限性
- 验证仅基于丹麦人群,外部适用性需在其他人群中进一步验证。
- 训练集和验证集均为吸烟者,非吸烟人群的适用性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lung cancer screening reduces lung cancer mortality, but identifying high-risk individuals remains difficult. We wanted to develop a blood test-based risk model (CPH-Lung) to improve risk stratification before image-based screening. MATERIALS AND METHODS: We included individuals from two prospective general population cohorts to model 6-year lung cancer risk; the Copenhagen General Population Study (CGPS) for training and the Copenhagen City Heart Study (CCHS) for validation. We analyzed clinical and biochemical variables from ever-smokers (689 cases and 1,924 controls) nested within CGPS to train a 6-year lung cancer risk model. CPH-Lung was validated in a cohort of ever-smokers age ≥50 years in the Copenhagen City Heart Study (CCHS, 3,195 individuals) and compared with the validated PLCOm2012 model. RESULTS: There were 689 and 68 events of 6-year lung cancer in the CGPS and the CCHS. In the CCHS validation study, the CPH-Lung versus the PLCOm2012 yielded AUCs of 0.783 (95% CI, 0.731 to 0.835) versus 0.720 (95% CI, 0.669 to 0.770) for detection of all 6-year lung cancers (P = .0059). The discrimination was similar in the CGPS. At specificity of 77.7% (as would have been achieved using currently applied screening criteria, eg, NELSON or NLST), sensitivities were 57.6% versus 39.2% in women (P < .0001) and 61.4% versus 54.7% in men (P = .004) for CPH-Lung versus PLCOm2012. The mean age at diagnosis was 68.2 years (standard deviation [SD], 7.50) in the 120 individuals with lung cancer predicted exclusively by CPH-Lung compared with 76.5 years (SD, 8.04) in the 37 individuals predicted exclusively by PLCOm2012 (P < .0001). CONCLUSION: After inclusion of blood test information, the CPH-Lung model was more sensitive in the Danish population than PLCOm2012 for prediction of 6-year lung cancer risk particularly among women and younger individuals.
引用
- Skov-Jeppesen SM, Kobylecki CJ, Egstrand S, et al. Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung). J Clin Oncol. 2026. PMID: 42863103. doi:10.1200/JCO-25-02326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。